Impact of drug-eluting stents with different coating strategies on stent thrombosis: A meta-analysis of 19 randomized trials

被引:5
作者
Niu, Xiaowei [1 ]
Yang, Cuiling [2 ]
Chen, De [1 ]
He, Shengliang [1 ]
Yan, Dong [1 ]
Yao, Yali [3 ]
机构
[1] Lanzhou Univ, Clin Med Coll 1, Dept Cardiol, Lanzhou 730000, Gansu, Peoples R China
[2] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Infect Dis, Xian 710049, Shanxi, Peoples R China
[3] Lanzhou Univ, Affiliated Hosp 1, Dept Cardiol, Lanzhou 730000, Gansu, Peoples R China
关键词
drug-eluting stents; biodegradable polymers; permanent polymers; stent thrombosis; meta-analysis; CORONARY-ARTERY-DISEASE; 2-YEAR CLINICAL-OUTCOMES; BIODEGRADABLE POLYMER; DURABLE POLYMER; FOLLOW-UP; EVEROLIMUS; MULTICENTER; REVASCULARIZATION; RESTENOSIS; LEADERS;
D O I
10.5603/CJ.a2014.0002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Whether drug-eluting stents with biodegradable polymers (BP-DES) improve safety, especially with respect to stent thrombosis (ST) compared with permanent polymers DES (PP-DES), remains uncertain. We aimed to compare the short-and long-term outcomes and the ST risk in patients treated with BP-DES vs. PP-DES. Methods: We searched Medline, Embase, Web of science, CENTRAL databases, and conference proceedings/abstracts for randomized controlled trials (RCTs) comparing BP-DES with PP-DES. The primary endpoint was to compare the risks of overall and different temporal categories of definite/probable ST. Other clinical outcomes were target lesion revascularization (TLR), myocardial infarction (MI), and all-cause death in short-term (<= 1 year) and long-term follow-up. The meta-analyses were performed by computing odds ratios (ORs) with 95% confidence intervals (CIs) using a random-effects model. Results: Nineteen RCTs including 20,229 patients were analyzed. Overall, BP-DES significantly decreased the risks of very late definite/probable ST (OR 0.33; 95% CI 0.16-0.70), and TLR in long-term follow-up (OR 0.70; 95% CI 0.52-0.95) compared with PP-DES. There were no significant differences between the groups regarding MI incidence and mortality during both short and long follow-up periods. In stratified analyses, the long-term superiority of BP-DES was maintained only by using first-generation DES as the comparators. Conclusions: The present meta-analysis indicated that BP-DES were more efficacious than PP-DES at reducing the risks of very late ST and long-term TLR, but it could vary by heterogeneities in the use of PP-DES comparators. Additional rigorous RCTs with longer follow-up periods are warranted to verify these very promising long-term endpoints.
引用
收藏
页码:557 / 568
页数:12
相关论文
共 51 条
[1]   Two-year follow-up of the NEVO ResElution-l(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions [J].
Abizaid, Alexandre ;
Ormiston, John A. ;
Fajadet, Jean ;
Mauri, Laura ;
Schofer, Joachim ;
Verheye, Stefan ;
Dens, Joseph ;
Thuesen, Leif ;
Macours, Nathalie ;
Qureshi, Ayesha C. ;
Spaulding, Christian .
EUROINTERVENTION, 2013, 9 (06) :721-729
[2]   An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study [J].
Barlis, Peter ;
Regar, Evelyn ;
Serruys, Patrick W. ;
Dimopoulos, Konstantinos ;
van der Giessen, Willem J. ;
van Geuns, Robert-Jan M. ;
Ferrante, Giuseppe ;
Wandel, Simon ;
Windecker, Stephan ;
van Es, Gerrit-Anne ;
Eerdmans, Pedro ;
Jueni, Peter ;
di Mario, Carlo .
EUROPEAN HEART JOURNAL, 2010, 31 (02) :165-176
[3]  
Byrne R A, 2009, Minerva Cardioangiol, V57, P567
[4]   Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results [J].
Byrne, R. A. ;
Kufner, S. ;
Tiroch, K. ;
Massberg, S. ;
Laugwitz, K-L ;
Birkmeier, A. ;
Schulz, S. ;
Mehilli, J. .
HEART, 2009, 95 (18) :1489-1494
[5]   No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents [J].
Byrne, Robert A. ;
Kastrati, Adnan .
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (04) :429-432
[6]   Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease 3-Year Outcomes From a Randomized Clinical Trial [J].
Byrne, Robert A. ;
Kastrati, Adnan ;
Massberg, Steffen ;
Wieczorek, Anna ;
Laugwitz, Karl-Ludwig ;
Hadamitzky, Martin ;
Schulz, Stefanie ;
Pache, Juergen ;
Fusaro, Massimiliano ;
Hausleiter, Joerg ;
Schoemig, Albert ;
Mehilli, Julinda .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (13) :1325-1331
[7]   Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial [J].
Byrne, Robert A. ;
Kastrati, Adnan ;
Kufner, Sebastian ;
Massberg, Steffen ;
Birkmeier, K. Anette ;
Laugwitz, Karl-Ludwig ;
Schulz, Stefanie ;
Pache, Juergen ;
Fusaro, Massimiliano ;
Seyfarth, Melchior ;
Schoemig, Albert ;
Mehilli, Julinda .
EUROPEAN HEART JOURNAL, 2009, 30 (20) :2441-2449
[8]   Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison [J].
Cassese, Salvatore ;
Ndrepepa, Gjin ;
King, Lamin A. ;
Tada, Tomohisa ;
Fusaro, Massimiliano ;
Kastrati, Adnan .
HEART, 2012, 98 (22) :1632-1640
[9]  
Chevalier B, 2010, EUROINTERVENTION SH, V6, P39
[10]  
Chevalier Bernard, 2007, EuroIntervention, V2, P426